title: Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
abstract: This post hoc study used data from the naturalistic Schizophrenia Outpatient Health Outcomes study, assessing the factors associated with starting antipsychotic monotherapy and the annual rate and duration of antipsychotic monotherapy among patients initiating atypical antipsychotics (N = 6866). Descriptive and regression analyses were used. Factors associated with starting antipsychotic monotherapy at baseline were antipsychotic treatment for the first time, shorter duration of illness, less severe illness, and better social functioning. Baseline monotherapy was maintained throughout 12 months by 63.2% of patients and was significantly greater for olanzapine (66.8%) than for risperidone (62.8%), quetiapine (43.4%), or amisulpride (52.6%) (all p ≤ 0.01). The predicted mean number of days on baseline monotherapy was significantly longer for olanzapine than for risperidone, quetiapine, or amisulpride (all p < 0.01). Initiation of antipsychotic monotherapy at baseline is associated with select baseline patient characteristics. Olanzapine was found to have the highest monotherapy rate and the longest duration of maintained monotherapy, followed by risperidone, amisulpride, and quetiapine.
authors: Health Outcomes Research, Eli Lilly and Company, Windlesham, Surrey, United Kingdom. novick_diego@lilly.com
authors: Diego
authors: D
authors: Novick
authors: Haya
authors: H
authors: Ascher-Svanum
authors: Roberto
authors: R
authors: Brugnoli
authors: Jordan
authors: J
authors: Bertsch
authors: Jihyung
authors: J
authors: Hong
authors: Josep Maria
authors: JM
authors: Haro
mesh_terms: D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000627:therapeutic use; D005060:Europe; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D000077152:Olanzapine; D019338:Polypharmacy; D011446:Prospective Studies; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D013469:Sulpiride / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D013469:Sulpiride; D000077582:Amisulpride; D018967:Risperidone; D000077152:Olanzapine